3 completed, 2 recruiting, 1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Multisystem Inflammatory Syndrome in Children (MIS-C): new trials by email Literature Review of Multisystem Inflammatory Syndrome in Children (MIS-C) trials Research Report on Multisystem Inflammatory Syndrome in Children (MIS-C)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cardiovascular Assessment 5 Years After MIS-C Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection | Recruiting | Medical University of Warsaw | 90 | 2025-11-22 | 2026-06-22 | |
| Quality of Life in Children After Multisystem Inflammatory Syndrome in Children Multisystem Inflammatory Syndrome in Children (MIS-C) | Completed | Kristina Lah Tomulić | 85 | 2024-04-01 | 2026-10-21 | |
| Contrast Enhanced Ultrasound in COVID-19 Sulfur hexafluoride lipid-type A microspheres - Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C) | Phase 3 | Completed | Children's Hospital of Philadelphia | 4 | 2020-12-18 | 2024-07-30 |
| COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C SARS-CoV-2 and/or MIS-C Exposure - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C) | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 244 | 2020-11-19 | 2024-02-29 | |
| Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Multisystem Inflammatory Syndrome in Children (MIS-C) | Active not recruiting | Carelon Research | 1200 | 2020-09-30 | 2026-03-27 | |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 |
pediatric multisystem inflammatory disease, COVID-19 related (6) · COVID-19 (4) · Adrenal Insufficiency (1) · Arrhythmias, Cardiac (1) · Attention Deficit Disorder with Hyperactivity (1) · Bronchopulmonary Dysplasia (1) · Cellulitis (1) · Coronavirus Infections (1) · Down Syndrome (1) · Edema (1) · Heart Failure (1) · Hemophilia A (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Hyperaldosteronism (1)
Coronaviridae Infections (4) · Infections (4) · Lung Diseases (4) · Nidovirales Infections (4) · Pneumonia, Viral (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Coronavirus Infections (3) · Pneumonia (3) · Abnormalities, Multiple (1) · Adrenal Gland Diseases (1) · Adrenocortical Hyperfunction (1) · Attention Deficit and Disruptive Behavior Disorders (1)
Abatacept (1) · Albuterol (1) · Aminocaproic Acid (1) · Amiodarone (1) · Aspirin (1) · Azithromycin (1) · Beclomethasone (1) · Bosentan (1) · Budesonide (1) · Bumetanide (1) · Cefdinir (1) · Cefepime (1) · Ceftazidime (1) · Cephalexin (1) · Chlorothiazide (1)
Carelon Research (1) · Children's Hospital of Philadelphia (1) · Duke University (1) · Kristina Lah Tomulić (1) · Medical University of Warsaw (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (4) · Canada (2) · Croatia (1) · Poland (1)
Betty Diamond, MD (1) · Chi Hornik (1) · Ignacio Sanz, MD (1) · James D. Wilkinson, MD, MPH (1) · Jeremy Boss, PhD (1) · Natasha B Halasa, MD, MPH (1) · Olivia Martinez, PhD (1) · Sheri Krams, PhD (1) · Steven A. Webber, MBChB, MRCP (1) · Virginia Pascual, MD (1)